Results 81 to 90 of about 152,173 (217)

The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Background Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ from invasive disease, the ...
Suzanne M. Selvaggi
wiley   +1 more source

Feline infectious peritonitis: a coronavirus disease of cats [PDF]

open access: yesJournal of Small Animal Practice, 1978
Horzinek, M.C., Osterhaus, A.D.M.E.
openaire   +3 more sources

Cytological Features of Clear Cell Sarcoma in Exfoliative and Effusion Cytology Specimen—A Case Report and Literature Review

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Clear cell sarcoma of soft tissue (CCSST) with malignant effusion is a rare yet clinically aggressive appearance, which may pose a diagnostic pitfall with its overlapping cytomorphologic features with metastatic melanoma and carcinoma.
William H. Wu   +2 more
wiley   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi   +9 more
wiley   +1 more source

[Peritoneal diseases].

open access: yesRevista do Hospital das Clinicas, 1993
M, Polak, B, Bitelman
openaire   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy